US President Donald Trump signs 'Right-to-Try' bill for terminally ill patients

The new bill titled "Right to Try" allows terminally ill patients to seek drugs that are still experimental and not fully approved by the US Food and Drug Administration.

Published: 31st May 2018 07:01 AM  |   Last Updated: 31st May 2018 07:05 AM   |  A+A-

Image used for representational purpose

By IANS

WASHINGTON: US President Donald Trump on Wednesday signed a new bill titled "Right to Try" which allows terminally ill patients to seek drugs that are still experimental and not fully approved by the US Food and Drug Administration.

"As I proudly sign this bill, thousands of terminally ill Americans will have the help, the hope and the fighting chance -- and I think it's going to be better than chance -- that they will be cured, that they will be helped, that they will be able to be with their families for a long time, or maybe just for a longer time," Trump said, Xinhua reported. 

Under the legislation, patients who are near death, or who have a disease that is likely to lead to severely premature death, have the right to seek drug treatments that remain in clinical trials after passing phase 1 of the FDA approval process. 

The House on Tuesday voted 250-169 in favour of the bill, which the Senate passed in August. 

Advocates for the bill say it opens a door for terminally ill people in states that haven't passed such a law. Critics argue that the legislation disempowers the FDA and won't make it easier for the patients to access these drugs, local media reported. 

"This issue is about real people who are terminally ill, facing the end of the line, and want to have one more shot at life," said Starlee Coleman with the Goldwater Institute, a conservative public policy think tank based in Phoenix that supports right-to-try legislation.

Right-to-try laws exist in 40 of US 50 states. With the new federal legislation, Coleman argues, patients in states without these laws could save time accessing experimental treatments by eliminating FDA application requirements.

Opponents of the bill, including over 100 patient and provider advocacy groups, say it won't have a major impact on accessing treatments; on the contrary, it could have a detrimental effect on how the FDA safeguards people's health. 

It is unclear how many Americans have taken advantage of right-to-try laws because the vast majority of states do not have central reporting requirements, said local media reports, noting that there's no guarantee that insurance companies would pay for these treatments.

Stay up to date on all the latest World news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp